Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

12/11 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
21/09/26	SEK 0.4100	-8.48%	1,022,650
18/09/26	SEK 0.4480	+7.31%	3,780,673
17/09/26	SEK 0.4175	-8.74%	5,148,576
16/09/26	SEK 0.4575	-0.33%	1,768,715
15/09/26	SEK 0.4590	-1.18%	2,906,802

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Delayed Nasdaq Stockholm 06:31:24 21/09/26 pm AEST			5-day change	1st Jan Change
0.4100 ^SEK	-8.48%		-11.73%	-50.54%

12/09	Stockholm stocks ended Friday higher	FW
11/09	Calendar Monday September 14 - Friday September 18	FW

Market Cap	90.78M 9.2M 8.03M 7.58M 6.88M 12.89M 883M 12.95M 35.03M 449M 34.58M 33.81M 1.44B	P/E 2026 *	-1.66x	P/E 2027 *	-1.18x
Enterprise Value	74.78M 7.58M 6.61M 6.24M 5.67M 10.62M 728M 10.67M 28.86M 370M 28.48M 27.85M 1.19B	EV / Sales 2026 *	2.39x	EV / Sales 2027 *	-
Free-Float	46.92%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	ALZ	Delayed
CBOE		Real-time
Deutsche Boerse AG	78D	Delayed
Börse Stuttgart	78D	Delayed
CBOE		Real-time

12/09	Stockholm stocks ended Friday higher	FW
11/09	Calendar Monday September 14 - Friday September 18	FW
11/09	Alzinova: Redeye cuts justified value to SEK 0.90	FW
11/09	Asker plunges on double downgrade, OMXS30 index up 0.3 percent	FW
11/09	Asker plunges on choppy Stockholm market	FW
11/09	Stockholm's stock exchange is expected to open Friday on a mixed note	FW
11/09	Alzinova Resolves On Rights Issue Of SEK 51 Mln	RE
11/09	Alzinova Starts Preparations for Mid-stage Trial of Alzheimer's Disease Vaccine Candidate	MT
11/09	Alzinova AB Initiates Operational Start-Up Of Global Phase 2 Study With ALZ-101	CI
20/08	Alzinova AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
20/08	RX Securities reiterates buy on Alzinova, justified value SEK 3.50	FW
20/08	Alzinova reports reduced operating loss	FW
20/08	Calendar Thursday, August 20	FW

Alzinova AB Stock

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation: Alzinova AB

Chart: Alzinova AB

Latest news: Alzinova AB

Analysts' recommendations: Alzinova AB

Press Releases: Alzinova AB

Quotes and Performance

Price Extremes

Managers and Directors: Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

18/09	Alzinova publishes information memorandum in connection with rights issue of units	AQ
11/09	Alzinova: Phase II study update and SEK51 rights issue	AQ
11/09	Alzinova: ALZ-101 enters Phase II start-up as Alzinova raises capital	AQ
11/09	The Board of Directors of Alzinova resolves on a rights issue of units of approximately SEK 51 million	AQ
11/09	Alzinova initiates operational start-up of global Phase 2 study with ALZ-101	AQ

1 day	-8.48%
1 week	-11.73%
Current month	-48.75%
1 month	-49.94%
3 months	-17.84%
6 months	-32.79%
Current year	-50.54%

1 week	0.4	0.47
1 month	0.4	1.04
Current year	0.38	1.61
1 year	0.38	2.28
3 years	0.38	4.62
5 years	0.38	8.7
10 years	0.38	44.9

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	01/10/2024
Anders Sandberg COO	Chief Operating Officer	54	17/08/2011
Erik Kullgren DFI	Director of Finance/CFO	57	27/03/2024

Director	Title	Age	Since
Clas Malmeström BRD	Director/Board Member	61	01/09/2015
Anders Waas BRD	Director/Board Member	69	01/01/2018
Carol Routledge BRD	Director/Board Member	-	01/01/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	-8.48%	-11.73%	-64.35%	-86.36%	9.2M
LONZA GROUP AG	+0.99%	+2.73%	+1.48%	+28.74%	46.28B
IQVIA HOLDINGS INC.	-1.12%	+1.78%	+42.30%	+29.70%	43.85B
REVOLUTION MEDICINES, INC.	-3.04%	-6.29%	+338.56%	+542.28%	40.93B
BEONE MEDICINES AG	-0.74%	+1.25%	+4.92%	+81.93%	39.89B
CELLTRION, INC.	-0.50%	+0.67%	+10.29%	+41.57%	29.5B
MEDPACE HOLDINGS, INC.	-0.46%	+4.22%	+22.81%	+140.41%	17.09B
ASCENDIS PHARMA A/S	-0.97%	-10.17%	-	-	15.55B
EUROFINS SCIENTIFIC SE	+0.86%	+6.85%	+23.01%	+39.47%	15.22B
TEMPUS AI, INC.	-3.14%	+31.91%	-11.79%	-	14.05B
Average	-1.66%	+2.91%	+40.80%	+102.22%	26.24B
Weighted average by Cap.	-0.86%	+1.87%	+68.28%	+138.85%

	2026 *	2027 *
Net sales	31.35M 3.18M 2.77M 2.62M 2.38M 4.45M 305M 4.47M 12.1M 155M 11.94M 11.68M 499M	-
Net income	-4.45M -451K -393K -371K -337K -632K -43.29M -635K -1.72M -22.01M -1.69M -1.66M -70.82M	-77M -7.81M -6.81M -6.43M -5.84M -10.94M -749M -10.98M -29.71M -381M -29.33M -28.68M -1.23B
Net Debt	-16M -1.62M -1.41M -1.34M -1.21M -2.27M -156M -2.28M -6.17M -79.14M -6.09M -5.96M -255M	-19M -1.93M -1.68M -1.59M -1.44M -2.7M -185M -2.71M -7.33M -93.98M -7.24M -7.08M -302M